These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
77 related articles for article (PubMed ID: 10812445)
1. [Clinical evaluation of efficacy and adverse effects in the (European) registration of drugs: what does it mean for the doctor and patient?]. Koopmans PP; de Graeff PA; van Zwieten-Boot BJ; Lekkerkerker JF; Broekmans AW Ned Tijdschr Geneeskd; 2000 Apr; 144(16):756-61. PubMed ID: 10812445 [TBL] [Abstract][Full Text] [Related]
2. How to anticipate the assessment of the public health benefit of new medicines? Massol J; Puech A; Boissel JP; Therapie; 2007; 62(5):427-35. PubMed ID: 18206104 [TBL] [Abstract][Full Text] [Related]
3. Availability of comparative trials for the assessment of new medicines in the European Union at the moment of market authorization. van Luijn JC; Gribnau FW; Leufkens HG Br J Clin Pharmacol; 2007 Feb; 63(2):159-62. PubMed ID: 17166187 [TBL] [Abstract][Full Text] [Related]
4. Choice of comparator in active control trials of new drugs. van Luijn JC; van Loenen AC; Gribnau FW; Leufkens HG Ann Pharmacother; 2008 Nov; 42(11):1605-12. PubMed ID: 18957629 [TBL] [Abstract][Full Text] [Related]
5. Comparators (medicinal and non medicinal) for marketing authorization, for public health, for payers and at the European level. Berdaï D; Hotton JM; Lechat P; Therapie; 2010; 65(4):329-34. PubMed ID: 20854755 [TBL] [Abstract][Full Text] [Related]
6. Tolcapone: new drug. In Parkinson's disease: unacceptable risk of severe hepatitis. Prescrire Int; 2006 Apr; 15(82):54-7. PubMed ID: 16604736 [TBL] [Abstract][Full Text] [Related]
7. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626 [TBL] [Abstract][Full Text] [Related]
8. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy. Van Vaerenbergh K Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503 [TBL] [Abstract][Full Text] [Related]
9. Drugs for rare diseases: mixed assessment in Europe. Prescrire Int; 2007 Feb; 16(87):36-42. PubMed ID: 17323539 [TBL] [Abstract][Full Text] [Related]
10. Ziconotide: new drug. Limited analgesic efficacy, too many adverse effects. Prescrire Int; 2008 Oct; 17(97):179-82. PubMed ID: 19530373 [TBL] [Abstract][Full Text] [Related]
11. [New drugs and European procedures of approval. The European Agency for the Evaluation of Medicinal Products' role]. Ainsworth MA Ugeskr Laeger; 2003 Apr; 165(16):1648-9. PubMed ID: 12756819 [TBL] [Abstract][Full Text] [Related]
12. Antiviral drugs in influenza: an adjunct to vaccination in some situations. Prescrire Int; 2006 Feb; 15(81):21-30. PubMed ID: 16548114 [TBL] [Abstract][Full Text] [Related]
13. [European guideline for the quality of non-commercial clinical trials: elegant implementation in the Netherlands via the amended Dutch Medical Research Involving Human Subjects Act]. Cohen AF Ned Tijdschr Geneeskd; 2003 Aug; 147(31):1493-5. PubMed ID: 12924078 [TBL] [Abstract][Full Text] [Related]
14. Etanercept: new preparation. Useful after methotrexate failure in inflammatory rheumatism. Prescrire Int; 2003 Aug; 12(66):127-32. PubMed ID: 12906020 [TBL] [Abstract][Full Text] [Related]
15. [European ordinance on orphan drugs: changes and threats]. Linthorst GE; Hollak CE Ned Tijdschr Geneeskd; 2003 Jan; 147(4):143-5. PubMed ID: 12635543 [TBL] [Abstract][Full Text] [Related]
16. [The role of the Danish Medical Products Agency in clinical trials]. Simonsen AC Ugeskr Laeger; 2003 Apr; 165(16):1653-6. PubMed ID: 12756821 [TBL] [Abstract][Full Text] [Related]
18. Ezetimibe: new preparation. A cholesterol-lowering drug with no clinical advantage. Prescrire Int; 2004 Oct; 13(73):176-9. PubMed ID: 15499698 [TBL] [Abstract][Full Text] [Related]
19. Procedures and methods of benefit assessments for medicines in Germany. Bekkering GE; Kleijnen J Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905 [TBL] [Abstract][Full Text] [Related]
20. Inhaled human insulin: new drug. No short-term advantages, too many unknowns in the long term. Prescrire Int; 2006 Dec; 15(86):203-9. PubMed ID: 17165235 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]